New Drug Slows Metastatic Prostate Cancer

June 2, 2014 5:35 PM

14 0

(HealthDay News) — Enzalutamide, an oral androgen-receptor inhibitor, is superior to placebo for the treatment of metastatic prostate cancer before chemotherapy, according a study published online June 1 in the New England Journal of Medicine. This research was published to coincide with the annual meeting of the American Society of Clinical Oncology, held from May 30–June 3 in Chicago.

Tomasz M. Beer, MD, of the Oregon Health and Science University in Portland, and colleagues randomly assigned 1,717 patients with metastatic prostate cancer to receive either enzalutamide or placebo.

Read more

To category page